

Andrea Fagiolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/395838/publications.pdf>

Version: 2024-02-01

252
papers

10,749
citations

34105

52
h-index

42399

92
g-index

282
all docs

282
docs citations

282
times ranked

9355
citing authors

#	ARTICLE	IF	CITATIONS
1	Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. <i>CNS Spectrums</i> , 2023, 28, 90-97.	1.2	11
2	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , 2022, 54, 90-99.	0.7	5
3	Eating disorders and autism spectrum: links and risks. <i>CNS Spectrums</i> , 2022, 27, 272-280.	1.2	28
4	Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 359-370.	3.2	11
5	Which mixed depression model? A comparison between DSMâ€¢defined mixed features and Koukopoulos' criteria. <i>Bipolar Disorders</i> , 2022, 24, 530-538.	1.9	3
6	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	7.9	68
7	Impact of menstrual cycle events on bipolar disorder course: a narrative review of current evidence. <i>Archives of Women's Mental Health</i> , 2022, 25, 257-266.	2.6	1
8	Emotional blunting in patients with depression. Part I: clinical characteristics. <i>Annals of General Psychiatry</i> , 2022, 21, 10.	2.7	13
9	Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 877867.	2.6	3
10	Exploration of mood spectrum symptoms during a major depressive episode: The impact of contrapolarityâ€¢Results from a transdiagnostic cluster analysis on an Italian sample of unipolar and bipolar patients. <i>European Psychiatry</i> , 2022, 65, .	0.2	4
11	Emotional blunting in patients with depression. Part III: relationship with psychological trauma. <i>Annals of General Psychiatry</i> , 2022, 21, .	2.7	2
12	Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life. <i>Annals of General Psychiatry</i> , 2022, 21, .	2.7	4
13	Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions. <i>Annals of General Psychiatry</i> , 2022, 21, .	2.7	1
14	Circadian neuromarkers of mood disorders. <i>Journal of Affective Disorders Reports</i> , 2022, 10, 100384.	1.7	2
15	Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. <i>Microbial Biotechnology</i> , 2021, 15, 1136-1145.	1.7	23
16	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	2.6	38
17	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <i>Journal of Psychiatric Research</i> , 2021, 133, 82-92.	3.1	27
18	Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. <i>Journal of Affective Disorders</i> , 2021, 283, 472-479.	4.1	46

#	ARTICLE	IF	CITATIONS
19	Convergence between clinician-rated and patient-reported PTSD symptoms in a specialized outpatient service: The moderator role of gender. <i>Perspectives in Psychiatric Care</i> , 2021, 57, 761-769.	1.9	1
20	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.2	15
21	A new approach for seasonal pattern: is it related to bipolarity dimension? Findings from an Italian multicenter study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 73-81.	2.4	3
22	Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 628965.	2.6	6
23	Autism spectrum in patients with schizophrenia: correlations with real-life functioning, resilience, and coping styles. <i>CNS Spectrums</i> , 2021, , 1-11.	1.2	10
24	Investigating the Relationship between Autistic Traits, Ruminative Thinking, and Suicidality in a Clinical Sample of Subjects with Bipolar Disorder and Borderline Personality Disorder. <i>Brain Sciences</i> , 2021, 11, 621.	2.3	29
25	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	11.0	89
26	DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis – A narrative review from the ECNP bipolar disorders network. <i>European Neuropsychopharmacology</i> , 2021, 47, 54-61.	0.7	25
27	Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 613-614.	1.4	1
28	Physical Activity Monitoring Preferences in Adults With Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 657043.	2.6	1
29	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 26.	2.2	6
30	Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. <i>Journal of Affective Disorders</i> , 2021, 294, 924-931.	4.1	14
31	Patient Safety and Risk Management in Mental Health. , 2021, , 287-298.		2
32	Biomarkers, Inflammation, and Bipolar Disorder: Association Between the Improvement of Bipolar Disorder Severity and the Improvement in C-Reactive Protein Levels After 7 Days of Inpatient Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 803034.	2.6	4
33	Mood spectrum symptoms during a major depressive episode: Differences between 145 patients with bipolar disorder and 155 patients with major depressive disorder. Arguments for a dimensional approach. <i>Bipolar Disorders</i> , 2020, 22, 385-391.	1.9	8
34	One Month Weight Loss Predicts the Efficacy of Liraglutide in Obese Patients: Data from A Single Center. <i>Endocrine Practice</i> , 2020, 26, 235-240.	2.1	8
35	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	10.4	96
36	Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. <i>Annals of General Psychiatry</i> , 2020, 19, 55.	2.7	30

#	ARTICLE	IF	CITATIONS
37	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52
38	Metacognitions and repetitive negative thinking in bipolar disorder and healthy controls: A comparative study. <i>Journal of Affective Disorders</i> , 2020, 276, 152-158.	4.1	8
39	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094270.	2.7	21
40	S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. <i>Annals of General Psychiatry</i> , 2020, 19, 50.	2.7	25
41	Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. <i>Psychopharmacology</i> , 2020, 237, 3497-3501.	3.1	10
42	Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. <i>Bipolar Disorders</i> , 2020, 22, 440-460.	1.9	66
43	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.9	40
44	Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action. <i>European Neuropsychopharmacology</i> , 2020, 36, 121-136.	0.7	17
45	Lithium and suicide prevention in mood disorders and in the general population: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 116, 142-153.	6.1	68
46	Schizophrenia and "unmet needs": From diagnosis to care in Italy. <i>European Psychiatry</i> , 2020, 63, e26.	0.2	9
47	Advances in treatment for postpartum major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1685-1698.	1.8	5
48	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2020, 35, 137-146.	1.7	26
49	Predictors of Depressive Switch in Patients With Bipolar I Disorder Who Initiated or Changed Pharmacologic Treatment for Mania or Mixed-Mania. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	4
50	COVID-19 Diary From a Psychiatry Department in Italy. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	81
51	Unmet Needs in the Assessment and Treatment of Psychomotor Agitation. , 2020, , 109-123.		1
52	Cariprazine in the management of negative symptoms of schizophrenia: state-of-the-art and future perspectives. <i>Future Neurology</i> , 2020, 15, .	0.5	7
53	Correlates of current rapid-cycling bipolar disorder: Results from the Italian multicentric RENDiBi study. <i>European Psychiatry</i> , 2019, 62, 82-89.	0.2	9
54	Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 679-690.	1.8	20

#	ARTICLE	IF	CITATIONS
55	Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 772-781.	2.3	19
56	<p>Rumination, posttraumatic stress disorder, and mood symptoms in borderline personality disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1231-1238.	2.2	34
57	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
58	The Effects of Terrorist Attacks on Symptom Clusters of PTSD: a Comparison with Victims of Other Traumatic Events. <i>Psychiatric Quarterly</i> , 2019, 90, 587-599.	2.1	10
59	Drug safety evaluation of aripiprazole in bipolar disorder. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 455-463.	2.4	18
60	Prevalence and Correlates of Vitamin D Deficiency in a Sample of 290 Inpatients With Mental Illness. <i>Frontiers in Psychiatry</i> , 2019, 10, 167.	2.6	33
61	Association between solar insolation and a history of suicide attempts in bipolar I disorder. <i>Journal of Psychiatric Research</i> , 2019, 113, 1-9.	3.1	25
62	Gender-related differences in patients with bipolar disorder: a nationwide study. <i>CNS Spectrums</i> , 2019, 24, 589-596.	1.2	15
63	Psychological and Brain Connectivity Changes Following Trauma-Focused CBT and EMDR Treatment in Single-Episode PTSD Patients. <i>Frontiers in Psychology</i> , 2019, 10, 129.	2.1	24
64	Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity. <i>Frontiers in Psychiatry</i> , 2019, 9, 784.	2.6	13
65	Five-year follow-up of first-episode depression treated with psychodynamic psychotherapy or antidepressants. <i>Psychiatry Research</i> , 2019, 275, 27-30.	3.3	8
66	Post-traumatic stress disorder in Italy: a comprehensive evaluation of all the ICD comorbidities and gender-related differences. <i>BMC Research Notes</i> , 2019, 12, 747.	1.4	6
67	Personalized and precision medicine as informants for treatment management of bipolar disorder. <i>International Clinical Psychopharmacology</i> , 2019, 34, 189-205.	1.7	17
68	Lithium and valproate serum level fluctuations within the menstrual cycle. <i>International Clinical Psychopharmacology</i> , 2019, 34, 143-150.	1.7	6
69	Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice. <i>Frontiers in Psychiatry</i> , 2019, 10, 842.	2.6	9
70	Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice. <i>Psychiatry Research</i> , 2019, 272, 698-706.	3.3	8
71	A comparison of physical comorbidities in patients with posttraumatic stress disorder developed after a terrorist attack or other traumatic event. <i>Journal of Neuroscience Research</i> , 2019, 97, 543-553.	2.9	7
72	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 126-136.	2.6	12

#	ARTICLE	IF	CITATIONS
73	Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. <i>Rivista Di Psichiatria</i> , 2019, 54, 137-149.	0.6	11
74	Principi di farmacodinamica e farmacocinetica nello switch tra antipsicotici: focus su cariprazina. <i>Rivista Di Psichiatria</i> , 2019, 54, 1-6.	0.6	4
75	The impact of affective temperaments on clinical and functional outcome of Bipolar I patients that initiated or changed pharmacological treatment for mania. <i>Psychiatry Research</i> , 2018, 261, 473-480.	3.3	16
76	Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. <i>Journal of Affective Disorders</i> , 2018, 228, 229-237.	4.1	34
77	Correlates of autistic traits among patients with borderline personality disorder. <i>Comprehensive Psychiatry</i> , 2018, 83, 7-11.	3.1	60
78	Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers. <i>International Clinical Psychopharmacology</i> , 2018, 33, 131-139.	1.7	6
79	Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 169-177.	3.2	15
80	Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2018, 39, 315-320.	2.1	42
81	A study on the association of mood disorders and gluten-related diseases. <i>Psychiatry Research</i> , 2018, 260, 366-370.	3.3	7
82	Internet use by older adults with bipolar disorder: international survey results. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 20.	2.2	13
83	The Microbiome: A New Target for Research and Treatment of Schizophrenia and its Resistant Presentations? A Systematic Literature Search and Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 1040.	3.5	33
84	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	2.3	18
85	Medication-Associated Sexual Dysfunction in Patients with Mental Illness. <i>Trends in Andrology and Sexual Medicine</i> , 2018, , 251-262.	0.1	0
86	Using sertraline in postpartum and breastfeeding: balancing risks and benefits. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 719-725.	2.4	16
87	Healthcare professionals's™ perceptions on the emotional impact of having an inadequate response to antidepressant medications: survey and prospective patient audit. <i>Annals of General Psychiatry</i> , 2018, 17, 20.	2.7	5
88	Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder. <i>BMC Psychiatry</i> , 2018, 18, 33.	2.6	14
89	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. <i>Schizophrenia Research</i> , 2018, 201, 105-112.	2.0	52
90	Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2018, 16, 885-890.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. <i>Neuroendocrinology Letters</i> , 2018, 39, 205-208.	0.2	2
92	Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients. <i>Psychiatry Research</i> , 2017, 249, 159-166.	3.3	5
93	Psychoeducational intervention focused on healthy living improves psychopathological severity and lifestyle quality in psychiatric patients: preliminary findings from a controlled study. <i>Journal of Mental Health</i> , 2017, 26, 271-275.	1.9	18
94	Pharmacological treatment of mixed states. <i>CNS Spectrums</i> , 2017, 22, 186-195.	1.2	11
95	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , 2017, 247, 257-264.	3.3	32
96	On the centrality of mixed features in mood disorders: Listening to Kraepelin and Weygandt and moving forward. <i>Bipolar Disorders</i> , 2017, 19, 704-705.	1.9	7
97	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 285-294.	3.2	33
98	Effect of long-term valproate treatment on bone metabolism in patients with bipolar disorder: a pilot study. <i>European Neuropsychopharmacology</i> , 2017, 27, S867-S868.	0.7	0
99	Quality of life in children and adolescents with obsessive–compulsive disorder: a systematic review and meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 597-608.	2.2	35
100	Lithium in late-life mania: a systematic review. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 755-766.	2.2	50
101	Morphovolumetric changes after EMDR treatment in drug-naïve PTSD patients. <i>Rivista Di Psichiatria</i> , 2017, 52, 24-31.	0.6	20
102	Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 99.	2.2	12
103	Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2143-2147.	1.8	0
104	Online information seeking by patients with bipolar disorder: results from an international multisite survey. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 17.	2.2	35
105	Internet use by patients with bipolar disorder: Results from an international multisite survey. <i>Psychiatry Research</i> , 2016, 242, 388-394.	3.3	36
106	Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. <i>Stereotactic and Functional Neurosurgery</i> , 2016, 94, 371-378.	1.5	13
107	Adult obsessive–compulsive disorder and quality of life outcomes: A systematic review and meta-analysis. <i>Asian Journal of Psychiatry</i> , 2016, 22, 41-52.	2.0	62
108	An approach to revealing clinically relevant subgroups across the mood spectrum. <i>Journal of Affective Disorders</i> , 2016, 203, 265-274.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Practical guidance for prescribing trazodone extended-release in major depression. Expert Opinion on Pharmacotherapy, 2016, 17, 433-441.	1.8	11
110	Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opinion on Drug Safety, 2016, 15, 449-455.	2.4	11
111	Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 2016, 17, 86-128.	2.6	204
112	Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence?. Neuroscience and Biobehavioral Reviews, 2016, 61, 66-89.	6.1	40
113	Association between stressful life events and autoimmune diseases: A systematic review and meta-analysis of retrospective case-control studies. Autoimmunity Reviews, 2016, 15, 325-334.	5.8	97
114	PTSD in victims of terroristic attacks – a comparison with the impact of other traumatic events on patients' lives. Psychiatria Polska, 2016, 50, 907-921.	0.5	7
115	Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opinion on Pharmacotherapy, 2015, 16, 727-737.	1.8	19
116	Binge Eating Disorder. Journal of Addiction Medicine, 2015, 9, 20-24.	2.6	1
117	Pharmacotherapy of Binge-Eating Disorder. Journal of Addiction Medicine, 2015, 9, 1-19.	2.6	16
118	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
119	Patterns of Antidepressant Use in Italy: Therapy Duration, Adherence and Switching. Clinical Drug Investigation, 2015, 35, 735-742.	2.2	15
120	Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder. CNS Drugs, 2015, 29, 725-740.	5.9	48
121	Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Current Pharmaceutical Design, 2015, 21, 3343-3351.	1.9	43
122	The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1750-1758.	1.4	13
123	Celiac and non-celiac gluten sensitivity: a review on the association with schizophrenia and mood disorders. Autoimmunity Highlights, 2014, 5, 55-61.	3.9	17
124	Telepsychiatry: new perspectives and open issues. CNS Spectrums, 2014, 19, 479-481.	1.2	14
125	Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. Journal of Affective Disorders, 2014, 156, 206-213.	4.1	51
126	Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. Journal of Affective Disorders, 2014, 152-154, 498-504.	4.1	93

#	ARTICLE	IF	CITATIONS
127	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	10.4	346
128	P.1.i.021 EMDR efficacy on characteristic posttraumatic stress disorder neurobiological alterations. <i>European Neuropsychopharmacology</i> , 2014, 24, S309.	0.7	0
129	Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context. <i>Advances in Therapy</i> , 2014, 31, 873-890.	2.9	12
130	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. <i>Journal of Affective Disorders</i> , 2014, 167, 104-111.	4.1	43
131	C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy. <i>Advances in Therapy</i> , 2013, 30, 697-712.	2.9	5
132	Season of Birth Is Associated With Adult Body Mass Index in Patients With Bipolar Disorder. <i>Chronobiology International</i> , 2013, 30, 577-582.	2.0	10
133	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 489-504.	1.8	8
134	Prevalence, chronicity, burden and borders of bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 148, 161-169.	4.1	141
135	Glutamate system as target for development of novel antidepressants. <i>CNS Spectrums</i> , 2013, 18, 188-198.	1.2	24
136	Validation of the Italian version of the Functioning Assessment Short Test (FAST) for bipolar disorder. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 187-194.	3.9	14
137	Catatonia and Neuroleptic Malignant Syndrome. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 36-42.	1.0	30
138	C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 611.	1.9	1
139	Photosensitivity and panic-agoraphobic spectrum: a pilot study. <i>Rivista Di Psichiatria</i> , 2013, 48, 108-12.	0.6	12
140	Inflammation, Serotonin and Major Depression. <i>Current Drug Targets</i> , 2013, 14, 571-577.	2.1	93
141	Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides. <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 2-10.	2.4	5
142	Rethinking the role of long-acting atypical antipsychotics in the community setting. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	1.7	27
143	Adherence to escitalopram treatment in depression. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	1.7	4
144	Rediscovering Trazodone for the Treatment of Major Depressive Disorder. <i>CNS Drugs</i> , 2012, 26, 1033-1049.	5.9	170

#	ARTICLE	IF	CITATIONS
145	Off-label uses of trazodone: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1707-1717.	1.8	63
146	Non-Monoaminergic Targets for the Development of Antidepressants: Focus on Neuropeptides. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 13, 2-10.	2.4	1
147	Impact of sunlight on the age of onset of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 654-663.	1.9	39
148	The Role of Psychomotor Activation in Discriminating Unipolar From Bipolar Disorders. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 22-28.	2.2	41
149	Cardiovascular Disease and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1563-1565.	2.2	42
150	Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. <i>Psychological Medicine</i> , 2011, 41, 151-162.	4.5	123
151	Bipolar spectrum: just broadening or an integration between categories and dimensions?. <i>World Psychiatry</i> , 2011, 10, 192-193.	10.4	1
152	Aripiprazole Augmentation in Clozapine-Associated Obsessive-Compulsive Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 375-376.	1.4	19
153	Does psychomotor retardation define a clinically relevant phenotype of unipolar depression?. <i>Journal of Affective Disorders</i> , 2011, 129, 296-300.	4.1	35
154	Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. <i>Depression and Anxiety</i> , 2011, 28, 303-309.	4.1	37
155	Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. <i>Depression and Anxiety</i> , 2011, 28, 955-962.	4.1	27
156	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2245-2263.	1.8	0
157	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. <i>Postgraduate Medicine</i> , 2011, 123, 135-159.	2.0	11
158	Aripiprazole for the treatment of bipolar disorder: a review of current evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 473-488.	1.8	7
159	Self-reported cognitive problems predict employment trajectory in patients with bipolar I disorder. <i>Journal of Affective Disorders</i> , 2010, 124, 324-328.	4.1	26
160	Comparative outcomes among the problem areas of interpersonal psychotherapy for depression. <i>Depression and Anxiety</i> , 2010, 27, 434-440.	4.1	10
161	A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 68-80.	2.1	12
162	Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1727-1740.	1.8	10

#	ARTICLE	IF	CITATIONS
163	Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 62-72.	2.0	60
164	Strategies for successful clinical management of schizophrenia with ziprasidone. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2199-2220.	1.8	15
165	The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 176-184.	2.0	13
166	Panic agoraphobic spectrum in psychiatrically healthy subjects: Impact on quality of life. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 65-68.	0.9	2
167	Sensitivity to Change and Predictive Validity of the MOODS-SR Questionnaire, Last-Month Version. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 116-124.	8.8	13
168	Light Therapy as a Treatment for Sexual Dysfunctions. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 127-128.	8.8	9
169	The structure of lifetime manic-hypomanic spectrum. <i>Journal of Affective Disorders</i> , 2009, 112, 59-70.	4.1	49
170	The factor structure of lifetime depressive spectrum in patients with unipolar depression. <i>Journal of Affective Disorders</i> , 2009, 115, 87-99.	4.1	46
171	Photosensitivity in panic disorder. <i>Depression and Anxiety</i> , 2009, 26, E34-E36.	4.1	18
172	Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study. <i>Bipolar Disorders</i> , 2009, 11, 382-390.	1.9	30
173	Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. <i>Bipolar Disorders</i> , 2009, 11, 657-662.	1.9	220
174	Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. <i>Bipolar Disorders</i> , 2009, 11, 701-710.	1.9	133
175	A multidimensional spectrum approach to post-traumatic stress disorder: comparison between the Structured Clinical Interview for Trauma and Loss Spectrum (SCI-TALS) and the Self-Report instrument (TALS-SR). <i>Comprehensive Psychiatry</i> , 2009, 50, 485-490.	3.1	91
176	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. <i>Asian Journal of Psychiatry</i> , 2009, 2, 106-111.	2.0	4
177	Chronotype and Body Composition in Bipolar Disorder. <i>Chronobiology International</i> , 2009, 26, 780-788.	2.0	51
178	Bipolar Disorder Center for Pennsylvanians: Implementing an Effectiveness Trial to Improve Treatment for At-Risk Patients. <i>Psychiatric Services</i> , 2009, 60, 888-897.	2.0	5
179	The Effects of Undertreated Chronic Medical Illnesses in Patients With Severe Mental Disorders. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 22-29.	2.2	165
180	Bipolar Disorder Center for Pennsylvanians: Implementing an Effectiveness Trial to Improve Treatment for At-Risk Patients. <i>Psychiatric Services</i> , 2009, 60, 888-97.	2.0	7

#	ARTICLE	IF	CITATIONS
181	Schizoaffective disorder: diagnostic issues and future recommendations. <i>Bipolar Disorders</i> , 2008, 10, 215-230.	1.9	142
182	Treatment of emergent mania/hypomania in unipolar patients. <i>Bipolar Disorders</i> , 2008, 10, 726-732.	1.9	24
183	Quality of life, anxiety and depression in Sarcoidosis. <i>General Hospital Psychiatry</i> , 2008, 30, 441-445.	2.4	50
184	Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. <i>Journal of Psychiatric Research</i> , 2008, 42, 956-961.	3.1	76
185	Impact of concurrent naturalistic pharmacotherapy on psychotherapy of complicated grief. <i>Psychiatry Research</i> , 2008, 159, 31-36.	3.3	47
186	Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. <i>Psychiatry Research</i> , 2008, 161, 51-58.	3.3	61
187	Physical health considerations in psychiatry: European views on recognition, monitoring and management. <i>European Neuropsychopharmacology</i> , 2008, 18, iii.	0.7	2
188	Overcoming hurdles to achieving good physical health in patients treated with atypical antipsychotics. <i>European Neuropsychopharmacology</i> , 2008, 18, S101-S107.	0.7	5
189	The Role of Interpersonal and Social Rhythm Therapy in Improving Occupational Functioning in Patients With Bipolar I Disorder. <i>American Journal of Psychiatry</i> , 2008, 165, 1559-1565.	7.2	146
190	Medical Burden in Late-Life Bipolar and Major Depressive Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 194-200.	1.2	78
191	Bipolar Disorder and the Metabolic Syndrome. <i>CNS Drugs</i> , 2008, 22, 655-669.	5.9	115
192	Aripiprazole: a discussion on its clinical use in mania associated with bipolar I disorder. <i>Drugs and Therapy Perspectives</i> , 2008, 24, 1.	0.6	1
193	A Psychoeducational Program for Weight Loss in Patients who have Experienced Weight Gain during Antipsychotic Treatment with Olanzapine. <i>Pharmacopsychiatry</i> , 2008, 41, 17-23.	3.3	54
194	Medication Effects in Neuroimaging Studies of Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2008, 165, 313-320.	7.2	312
195	Using Computerized Adaptive Testing to Reduce the Burden of Mental Health Assessment. <i>Psychiatric Services</i> , 2008, 59, 361-368.	2.0	200
196	Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. <i>Clinical Trials</i> , 2008, 5, 253-261.	1.6	24
197	Practical guidance for prescribing with aripiprazole in bipolar disorder. <i>Current Medical Research and Opinion</i> , 2008, 24, 2691-2702.	1.9	15
198	Quetiapine in post-transplant acute mania/bipolar disorder NOS. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 723-4.	2.1	1

#	ARTICLE	IF	CITATIONS
199	Integrating Medical and Psychiatric Care in Patients With Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 257-258.	1.4	7
200	Medical Monitoring in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, e16.	2.2	9
201	Metabolic Syndrome in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 678-679.	2.2	36
202	The Use of Antidepressants in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1307-1318.	2.2	54
203	A Prospective Observational Study of Obesity, Body Composition, and Insulin Resistance in 18 Women With Bipolar Disorder and 17 Matched Control Subjects. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1892-1900.	2.2	29
204	The Rabbit Syndrome: State of the Art. <i>Current Clinical Pharmacology</i> , 2007, 2, 212-216.	0.6	7
205	Newer antipsychotics and the rabbit syndrome. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2007, 3, 6.	1.2	22
206	Gender Differences in Bipolar Disorder Type 1. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 93-96.	1.0	29
207	Sexual Disorders in Subjects Treated for Mood and Anxiety Diseases. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 310-312.	1.4	21
208	Eating disorders and illness burden in patients with bipolar spectrum disorders. <i>Comprehensive Psychiatry</i> , 2007, 48, 516-521.	3.1	28
209	The long term "Maximising potential for rehabilitation in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, S123-S129.	0.7	3
210	Appropriate treatments for agitation associated with schizophrenia: Control of acute agitation and maintenance of efficacy. <i>European Psychiatry</i> , 2007, 22, S89-S90.	0.2	1
211	Aripiprazole in the Treatment of Schizophrenia. <i>Clinical Drug Investigation</i> , 2007, 27, 1-13.	2.2	22
212	Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder. <i>Bipolar Disorders</i> , 2007, 9, 462-467.	1.9	23
213	Quality of life and subthreshold obsessive-compulsive disorder. <i>Acta Neuropsychiatrica</i> , 2007, 19, 357-361.	2.1	9
214	Weight gain and metabolic issues of medicines used for bipolar disorder. <i>Current Psychiatry Reports</i> , 2007, 9, 521-528.	4.5	27
215	The Importance of Routine for Preventing Recurrence in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2006, 163, 981-985.	7.2	27
216	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. <i>American Journal of Psychiatry</i> , 2006, 163, 1450-1451.	7.2	13

#	ARTICLE	IF	CITATIONS
217	Effects of an Educational Intervention on Weight Gain in Patients Treated With Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 462-466.	1.4	21
218	Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. <i>Bipolar Disorders</i> , 2006, 8, 566-575.	1.9	118
219	Hypothyroidism in patients with Bipolar I Disorder treated primarily with lithium. <i>Epidemiologia E Psichiatria Sociale</i> , 2006, 15, 123-127.	0.9	41
220	Persistent Posttraumatic Stress Disorder Following September 11 in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 394-399.	2.2	35
221	Prevalence and Clinical Correlates of Medical Comorbidities in Patients With Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 783-788.	2.2	64
222	Obesity in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 904-915.	2.2	76
223	Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. <i>Psychopharmacology Bulletin</i> , 2006, 39, 120-46.	0.0	10
224	Functional impairment in the remission phase of bipolar disorder. <i>Bipolar Disorders</i> , 2005, 7, 281-285.	1.9	174
225	Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. <i>Bipolar Disorders</i> , 2005, 7, 424-430.	1.9	396
226	Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. <i>Depression and Anxiety</i> , 2005, 21, 140-142.	4.1	16
227	Cross-cultural validity of the Structured Clinical Interview for Panic-Agoraphobic Spectrum. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 283-290.	3.1	11
228	Quality of life and subthreshold affective symptoms. <i>Quality of Life Research</i> , 2005, 14, 905-909.	3.1	6
229	Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. <i>Annals of Medicine</i> , 2005, 37, 590-602.	3.8	39
230	A Pilot Study of Standardized Treatment in Geriatric Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 319-323.	1.2	28
231	A Pilot Study of Standardized Treatment in Geriatric Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 319-323.	1.2	28
232	The Mood Spectrum in Unipolar and Bipolar Disorder: Arguments for a Unitary Approach. <i>American Journal of Psychiatry</i> , 2004, 161, 1264-1269.	7.2	200
233	Personality pathology and outcome in recurrently depressed women over 2 years of maintenance interpersonal psychotherapy. <i>Psychological Medicine</i> , 2004, 34, 659-669.	4.5	56
234	Suicide Attempts and Ideation in Patients With Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 509-514.	2.2	85

#	ARTICLE	IF	CITATIONS
235	Development and preliminary testing of the General 5-Spectrum Measure (GSM-V). <i>Depression and Anxiety</i> , 2003, 18, 109-117.	4.1	7
236	Is treatment-resistant depression a unique subtype of depression?. <i>Biological Psychiatry</i> , 2003, 53, 640-648.	1.3	111
237	Obesity as a Correlate of Outcome in Patients With Bipolar I Disorder. <i>American Journal of Psychiatry</i> , 2003, 160, 112-117.	7.2	368
238	Suicide Attempts in Patients With Bipolar I Disorder During Acute and Maintenance Phases of Intensive Treatment With Pharmacotherapy and Adjunctive Psychotherapy. <i>American Journal of Psychiatry</i> , 2002, 159, 1160-1164.	7.2	93
239	Clinical Significance of Lifetime Panic Spectrum Symptoms in the Treatment of Patients With Bipolar I Disorder. <i>Archives of General Psychiatry</i> , 2002, 59, 905.	12.3	164
240	The panic-agoraphobic spectrum: development, description, and clinical significance. <i>Psychiatric Clinics of North America</i> , 2002, 25, 739-756.	1.3	22
241	Measuring Mood Spectrum: Comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. <i>Comprehensive Psychiatry</i> , 2002, 43, 69-73.	3.1	134
242	Conceptual underpinnings and empirical support for the mood spectrum. <i>Psychiatric Clinics of North America</i> , 2002, 25, 699-712.	1.3	59
243	Adult separation anxiety: psychometric properties of a new structured clinical interview. <i>Journal of Psychiatric Research</i> , 2002, 36, 77-86.	3.1	78
244	Clinical indicators for the use of antidepressants in the treatment of bipolar I depression. <i>Bipolar Disorders</i> , 2002, 4, 277-282.	1.9	15
245	Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 528-533.	2.2	172
246	Tolerability of Combined Treatment With Lithium and Paroxetine in Patients With Bipolar Disorder and Depression. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 474-478.	1.4	22
247	Anxiety as a Correlate of Response to the Acute Treatment of Bipolar I Disorder. <i>American Journal of Psychiatry</i> , 2000, 157, 956-962.	7.2	201
248	Influence of Panic-Agoraphobic Spectrum Symptoms on Treatment Response in Patients With Recurrent Major Depression. <i>American Journal of Psychiatry</i> , 2000, 157, 1101-1107.	7.2	113
249	The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. <i>Journal of Affective Disorders</i> , 1999, 54, 319-328.	4.1	210
250	Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI-MOODS). <i>International Journal of Methods in Psychiatric Research</i> , 1999, 8, 71-82.	2.1	75
251	Is Lifetime Separation Anxiety a Manifestation of Panic Spectrum?. <i>CNS Spectrums</i> , 1998, 3, 63-72.	1.2	20
252	Bipolar Disorders. , 0, , 155-174.		0